Tag:
chronic kidney disease
Latest Headlines
Latest Headlines
Takeda, Affymax nail supply deal for Omontys anemia drug
Takeda Pharmaceuticals and Affymax ($AFFY) have sewn up another supply deal for their anemia drug Omontys. DSI Renal, one of the largest dialysis providers in the U.S., agreed to adopt Omontys to treat their patients with chronic kidney disease.
Kidney problems tag development delays?
Malformed kidneys in newborn babies could be markers for mental illness and problems with behavior and understanding.
AstraZeneca strikes $272M deal for Ardelyx kidney drug
Under the new partnership, Adelyx gets $35 million up front, plus up to $237.5 million in milestones, provided the RX5791 drug makes it to market.
AstraZeneca bags PhIIb-ready CKD drug in $272M Ardelyx partnership
A deal-hungry AstraZeneca has bagged a Phase IIb-ready compound for chronic kidney disease in a $272 million deal with Fremont, CA-based Ardelyx. The pharma giant agreed to pay $35 million upfront to partner on Ardelyx's lead drug, RDX5791, which spurs the body to bypass vulnerable kidneys when it flushes sodium.
UNC biotech spinoff grabs J&J deal and $16M A round for diabetic nephropathy drug
Vascular Pharmaceuticals has nailed down $16 million in a Series A round of financing while revealing a deal that gives a unit of Johnson & Johnson an option to acquire the biotech, the company announced Wednesday. The injection of capital fuels the University of North Carolina (UNC) spinoff's efforts to advance its lead experimental drug to initial human studies as a new treatment for diabetic kidney disease.
Blood test may cut side effects in autoimmune kidney disease
A biomarker emerging from European research has potential to select out those patients who don't need immunosuppressive treatment for an autoimmune kidney disorder, and therefore could avoid exposure to unnecessary side effects.
UPDATED: Amgen snags KAI Pharma's CKD program in $315M buyout
In the latest in a string of biotech acquisitions, Amgen says it is buying KAI Pharmaceuticals for $315 million in cash.
Could kidney damage biomarkers speed drug development?
Drug-induced kidney injury is an important issue for patients, and current biomarkers can bring up false positives, causing drug developers to abandon projects too early. A new collaboration will
Elevated hormone FGF23 could indicate kidney failure imminent
Researchers have found a hormone that, if elevated, could catch kidney failure before it happens. But, first, a little background on phosphorus. Just enough phosphorus in our bodies is a good thing.
Three-biomarker combo may better predict kidney failure
Researchers at the San Francisco VA Medical Center think they have found a better way to predict risk of kidney failure and death with a combined use of three biomarkers. Currently, chronic kidney
